Edition:
India

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

4.84USD
6 Dec 2019
Change (% chg)

$0.02 (+0.41%)
Prev Close
$4.82
Open
$4.95
Day's High
$5.07
Day's Low
$4.82
Volume
1,412,007
Avg. Vol
2,372,560
52-wk High
$12.48
52-wk Low
$1.97

Latest Key Developments (Source: Significant Developments)

Endo Announces FDA Acceptance Of Original Biologics License Application For Collagenase Clostridium Histolyticum To Treat Cellulite
Wednesday, 20 Nov 2019 

Nov 19 (Reuters) - Endo International PLC ::ENDO ANNOUNCES FDA'S ACCEPTANCE OF ORIGINAL BIOLOGICS LICENSE APPLICATION (BLA) FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) IN PATIENTS WITH CELLULITE.ENDO INTERNATIONAL PLC - PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION DATE FOR BLA, HAS BEEN SET FOR JULY 6, 2020..ENDO INTERNATIONAL PLC - BLA FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IS SUPPORTED BY RESULTS OF RELEASE-1 AND RELEASE-2 PHASE 3 STUDIES.  Full Article

Endo Says No "Direct News" From FDA About Application For Approval Of Cellulite Treatment
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Endo International PLC ::ENDO CEO SAYS "WHILE SETTLEMENT REMAINS OUR GOAL, WE ARE PREPARED TO LITIGATE IF NECESSARY" IN REFERENCE TO OPIOID LAWSUITS - CONF. CALL.ENDO SAYS CONTINUING TO TAKE APPROPRIATE STEPS TO PREPARE FOR REGULATORY APPROVAL OF CELLULITE TREATMENT IN SECOND HALF OF 2020 - CONF. CALL.ENDO SEES HIGH LEVEL OF COMPETITION IN GENERICS BUSINESS DRIVEN BY NEW MARKET ENTRANTS - CONF. CALL.ENDO SEES 2019 BRANDED SPECIALTY PRODUCT PORTFOLIO REVENUE GROWING IN MID TEENS PERCENTAGE VERSUS. PRIOR EXPECTATION OF LOW DOUBLE DIGIT PERCENTAGE - CONF. CALL.ENDO RAISES 2019 XIAFLEX SALES GROWTH FORECAST TO ABOUT 20% VERSUS. PRIOR VIEW OF MID TO HIGH TEENS PERCENTAGE.ENDO SAYS 2019 VASOSTRICT REVENUE EXPECTED TO GROW IN LOW DOUBLE DIGIT PERCENT - CONF. CALL.ENDO CEO SAYS DECISION TO RESIGN WAS A PERSONAL LIFE DECISION, SAYS BELIEVES CO IS IN "BEST POSITION FOR GROWTH" - CONF. CALL.ENDO CEO SAYS "NOTHING STOPPING US" FROM BRINGING IN SMALL DEALS FOR SPECIALTY AND STERILE INJECTABLES BUSINESSES - CONF. CALL.ENDO SAYS NO "DIRECT NEWS" FROM FDA ABOUT CO'S APPLICATION FOR APPROVAL OF TREATMENT FOR CELLULITE - CONF. CALL.  Full Article

Endo Implements Says Chief Executive Officer Paul Campanelli To Retire
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - Endo International PLC ::ENDO IMPLEMENTS CEO SUCCESSION PLAN.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI APPOINTED CHAIRMAN OF BOARD.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI WILL ALSO CONTINUE AS PRESIDENT AND CHIEF EXECUTIVE OFFICER UNTIL SUCCESSOR APPOINTED.ENDO INTERNATIONAL - PAUL V. CAMPANELLI, PRESIDENT AND CHIEF EXECUTIVE OFFICER HAS NOTIFIED BOARD OF DIRECTORS OF HIS INTENTION TO RETIRE.  Full Article

Endo Implements CEO Succession Plan
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - Endo International PLC ::ENDO IMPLEMENTS CEO SUCCESSION PLAN.ENDO INTERNATIONAL PLC - ROGER KIMMEL APPOINTED SENIOR INDEPENDENT DIRECTOR.ENDO INTERNATIONAL PLC - PAUL CAMPANELLI APPOINTED CHAIRMAN OF BOARD, WILL ALSO CONTINUE AS PRESIDENT AND CEO UNTIL SUCCESSOR APPOINTED.ENDO INTERNATIONAL PLC - BOARD IS LAUNCHING A PROCESS TO IDENTIFY CAMPANELLI'S SUCCESSOR.  Full Article

Endo International Reports Q3 GAAP Loss Per Share Of $0.18 From Continuing Operations
Tuesday, 5 Nov 2019 

Nov 4 (Reuters) - Endo International PLC ::ENDO REPORTS THIRD-QUARTER 2019 FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.60 FROM CONTINUING OPERATIONS.Q3 GAAP LOSS PER SHARE $0.18 FROM CONTINUING OPERATIONS.Q3 REVENUE $729 MILLION VERSUS REFINITIV IBES ESTIMATE OF $711.3 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.53 -- REFINITIV IBES DATA.ENDO INTERNATIONAL - 2019 FINANCIAL GUIDANCE UPDATED TO NARROW EXPECTED RANGES FOR REVENUE, ADJUSTED DILUTED NET INCOME PER SHARE FROM CONTINUING OPERATIONS & ADJUSTED EBITDA.QTRLY BRANDED PHARMACEUTICALS REVENUES WERE $217 MILLION COMPARED TO $220 MILLION.SPECIALTY PRODUCTS REVENUES INCREASED 18% TO $132 MILLION IN THIRD-QUARTER 2019.SEES 2019 TOTAL REVENUES TO BE BETWEEN $2.86 BILLION AND $2.89 BILLION.SEES 2019 ADJUSTED DILUTED NET INCOME PER SHARE FROM CONTINUING OPERATIONS TO BE BETWEEN $2.10 AND $2.25.FY2019 EARNINGS PER SHARE VIEW $2.17, REVENUE VIEW $2.87 BILLION -- REFINITIV IBES DATA.  Full Article

Endo Announces Submission Of Biologics License Application To FDA For CCH In Patients With Cellulite
Friday, 6 Sep 2019 

Sept 6 (Reuters) - Endo International PLC ::ENDO ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (CCH) IN PATIENTS WITH CELLULITE.SUBMISSION IS BASED ON POSITIVE RESULTS FROM TWO IDENTICAL PHASE 3 RELEASE STUDIES.  Full Article

Endo Announces Execution Of Settlement Agreement & Release Resolving "Track 1" Opioid Cases
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Endo International PLC ::ENDO ANNOUNCES EXECUTION OF FINAL SETTLEMENT AGREEMENT AND RELEASE RESOLVING "TRACK 1" OPIOID CASES.ENDO INTERNATIONAL PLC - ENDO WILL PAY A TOTAL SUM OF $10 MILLION.ENDO INTERNATIONAL - AGREEMENT RESOLVES CLAIMS THAT WERE OR COULD HAVE BEEN ASSERTED BY 2 PLAINTIFF COUNTIES AGAINST ENDO ENTITIES IN TRACK 1 CASES.ENDO INTERNATIONAL PLC - ENDO WILL PROVIDE UP TO $1 MILLION OF ITS VASOSTRICT AND ADRENALIN PRODUCTS FREE OF CHARGE.ENDO INTERNATIONAL PLC - CUYAHOGA COUNTY WILL RECEIVE $6.2 MILLION IN CASH AND UP TO $620,000 OF VASOSTRICT AND/OR ADRENALIN.ENDO INTERNATIONAL PLC - SUMMIT COUNTY WILL RECEIVE $3.8 MILLION IN CASH AND UP TO $380,000 OF VASOSTRICT AND/OR ADRENALIN.ENDO - IN EVENT OF RESOLUTION OF GOVERNMENT-RELATED OPIOID CLAIMS, 2 PLAINTIFF COUNTIES WILL GET VALUE THEY WOULD'VE RECEIVED LESS VALUE OF SETTLEMENT DEAL.ENDO INTERNATIONAL - SETTLEMENT AGREEMENT INCLUDES NO ADMISSION OF WRONGDOING, FAULT OR LIABILITY OF ANY KIND BY ENDO ENTITIES.  Full Article

Endo International Q2 Adjusted Earnings Per Share $0.52 From Continuing Operations
Tuesday, 6 Aug 2019 

Endo International PLC ::ENDO REPORTS SECOND-QUARTER 2019 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.52 FROM CONTINUING OPERATIONS.Q2 GAAP LOSS PER SHARE $0.43 FROM CONTINUING OPERATIONS.Q2 REVENUE $700 MILLION VERSUS REFINITIV IBES ESTIMATE OF $695.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.48 -- REFINITIV IBES DATA.ENDO REAFFIRMS FULL-YEAR 2019 FINANCIAL GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $2.17, REVENUE VIEW $2.87 BILLION -- REFINITIV IBES DATA.  Full Article

Helsinn And Endo Announce Agreement For Paladin Labs Inc To Commercialize Pracinostat In Canada
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Endo International PLC ::HELSINN AND ENDO ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE PRACINOSTAT IN CANADA.ENDO INTERNATIONAL-UNIT ENTERED AGREEMENTS WITH HELSINN TO COMMERCIALIZE, &DISTRIBUTE PRACINOSTAT ON AN EXCLUSIVE BASIS IN CANADA UPON REGULATORY APPROVAL.ENDO INTERNATIONAL PLC - HELSINN TO BE RESPONSIBLE FOR SUPPLYING DRUG TO PALADIN, WILL RETAIN INTERNATIONAL DEVELOPMENT RIGHTS.ENDO - PALADIN LABS INC WILL BE RESPONSIBLE FOR REGISTRATION, DISTRIBUTION, PRICING,OTHERS IN CONNECTION WITH PRACINOSTAT IN CANADA.  Full Article

Endo Q1 Adjusted Earnings Per Share $0.53 From Continuing Operations
Thursday, 9 May 2019 

May 9 (Reuters) - Endo International PLC ::ENDO REPORTS FIRST-QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.53 FROM CONTINUING OPERATIONS.Q1 GAAP LOSS PER SHARE $0.06 FROM CONTINUING OPERATIONS.Q1 REVENUE $720 MILLION VERSUS REFINITIV IBES ESTIMATE OF $691.8 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.43 -- REFINITIV IBES DATA.COMPANY AFFIRMS 2019 FINANCIAL GUIDANCE.AS OF MARCH 31, 2019, COMPANY HAD APPROXIMATELY $1.0 BILLION IN UNRESTRICTED CASH.FY2019 EARNINGS PER SHARE VIEW $2.17, REVENUE VIEW $2.87 BILLION -- REFINITIV IBES DATA.  Full Article

UPDATE 1-Endo quarterly profit beat fueled by sterile injectables

Nov 4 Endo International Plc beat analysts' estimate for third-quarter profit and raised its full-year earnings forecast on Monday, driven by higher sales in its sterile injectables business.